`Date Filed: March 11, 2015
`
`Filed On Behalf Of:
`
`Novartis AG and LTS Lohmann Therapie-Systeme AG
`
`By:
`
`Raymond R. Mandra
`ExelonPatchIPR@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`NOVEN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`Inter Partes Review No. 2014-00550
`
`U.S. Patent 6,335,031
`
`UNOPPOSED MOTION TO FILE CORRECTED AND SUPPLEMENTAL
`PATENT OWNERS’ EXHIBITS AND CORRECTED EXHIBIT LIST
`
`
`
`Patent Owners Novartis AG and LTS Lohmann Therapie-Systeme AG
`
`respectfully move the Board for leave to submit corrected Exhibits 2012, 2023,
`
`2035, 2044, 2050, 2051 and supplemental Exhibit 2054 to their January 20, 2015
`
`Patent Owner Response and for leave to submit amended Patent Owners’ Exhibit
`
`List 3 as set forth below.
`
`On January 27, 2015, Noven Pharmaceuticals (“Petitioner”) served
`
`objections pursuant to 37 C.F.R § 42.64(b)(1) to all of Patent Owners’ filed
`
`exhibits. Petitioner’s objections included (i) general evidentiary objections and (ii)
`
`specific objections due to clerical and typographical errors addressed herein. On
`
`February 10, 2015, pursuant to 37 C.F.R § 42.64(b)(2), Patent Owners provided a
`
`list of corrections and supplemental evidence to address certain errors raised in
`
`Petitioner’s objections. In a communication dated February 18, 2015, Petitioner
`
`agreed that the proposed corrections and supplemental evidence cured the defects
`
`to which they were addressed but maintained all remaining objections. Patent
`
`Owners have provided the corrected and supplemental exhibits and amended
`
`Exhibit List 3 to the Petitioner, and Petitioner has stated that it does not oppose this
`
`motion.
`
`Patent Owners sought permission to file this motion, which was granted in
`
`an email from the Board on March 10, 2015.
`
`1
`
`
`
`To facilitate the Board’s review of this matter, Patent Owners seek
`
`permission to file the following exhibits and amended exhibit list to correct clerical
`
`and typographical errors:
`
`Exhibit 2012
`
`To correct the following clerical and typographical errors in paragraph 85
`
`and Appendix A paragraph 1 of Exhibit 2012, Patent Owners provide the
`
`Supplemental Declaration of Alexander M. Klibanov, Ph.D., dated February 10,
`
`2015, making the following corrections to Dr. Klibanov’s January 20, 2015
`
`Declaration:
`
` Paragraph 85: Change “(Ex. 2040, USP XX (1979) at 1079; Ex. 2041,
`
`USP XXII (1989) at 624.)” to “(Ex. 2040, United States Pharmacopeia and
`
`National Formulary (USP 20-NF 15), Rockville, MD: United States
`
`Pharmacopeial Convention, 1980 at 624; Ex. 2041, United States
`
`Pharmacopeia and National Formulary (USP 22-NF 17), Rockville, MD:
`
`United States Pharmacopeial Convention, 1990 at 1079.)”
`
` Appendix A, Paragraph 1: Change “(Ex. 40, Rosin, col. 4, ll. 21-53.)” to
`
`“(Ex. 1008, Rosin, col. 4, ll. 21-53.)”
`
`Exhibits 2023, 2035, 2044 and 2050
`
`To address, in part, Petitioner’s objections, Patent Owners provide
`
`replacement exhibits 2023, 2035, 2044, and 2050 with associated cover pages.
`
`2
`
`
`
`Patent Owners request permission to file an amended Exhibit List 3 to
`
`clarify the entry for Exhibit 2023:
`
` Change “U.S. Pharmacopeial Convention, Revision Bulletin, Clonidine
`
`Transdermal System (Jan. 1, 2011)” to “U.S. Pharmacopeial Convention,
`
`Revision Bulletin, Clonidine Transdermal System (Jan. 1, 2011)
`
`incorporated into United States Pharmacopeia and National Formulary (USP
`
`34-NF 29) Supplement 2, 5407-5410, Rockville, MD: United States
`
`Pharmacopeial Convention, 2011”
`
`Exhibits 2040 and 2041
`
`To address, in part, Petitioner’s objections to Exhibits 2040 and 2041, Patent
`
`Owners request permission to file an amended Exhibit List 3 with the following
`
`corrections:
`
` The entry for Exhibit 2040 change “The United States Pharmacopeia, 624-
`
`625 (20th ed., 1979) (Entry for Physostigmine Salicylate Injection)” to
`
`“United States Pharmacopeia and National Formulary (USP 20-NF 15),
`
`624-625, Rockville, MD: United States Pharmacopeial Convention, 1980”
`
` The entry for Exhibit 2041 change “The United States Pharmacopeia, 1078-
`
`1079 (22nd ed., 1989) (Entry for Physostigmine Salicylate Injection)” to
`
`“United States Pharmacopeia and National Formulary (USP 22-NF 17),
`
`3
`
`
`
`1078-1079, Rockville, MD: United States Pharmacopeial Convention,
`
`1990”
`
`Exhibit 2047
`
`To address, in part, Petitioner’s objections to Exhibit 2047, Patent Owners
`
`provide the Declaration of Lisa Butler (supplemental Exhibit 2054), dated
`
`February 10, 2015.
`
`Exhibit 2051
`
`To address, in part, Petitioner’s objections to Exhibit 2051, Patent Owners
`
`provide a clean replacement copy of the exhibit.
`
`Dated: March 11, 2015
`
`Respectfully submitted,
`
`/Raymond R. Mandra/
`Raymond R. Mandra
`Registration No. 34,382
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the foregoing UNOPPOSED MOTION TO FILE
`CORRECTED AND SUPPLEMENTAL PATENT OWNERS’ EXHIBITS AND
`EXHBIT LIST was served on March 11, 2015 by causing it to be sent by email to
`counsel for Petitioner at the following email addresses:
`
`Steven J. Lee (slee@kenyon.com)
`
`Michael K. Levy (mlevy@kenyon.com)
`
`Chris Coulson (ccoulson@kenyon.com)
`
`Dated: March 11, 2015
`
`/Raymond R. Mandra/
`Raymond R. Mandra
`Registration No. 34,382
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`5
`
`